Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and payer ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...